BACKGROUND & AIMS: Bacteria might be involved in the development and persistence of
inflammation in patients with Crohn's disease (CD), and antibiotics could be used in therapy …

Aims Enteric bacteria are thought to contribute to the pathogenesis of Crohn's disease, and
antibiotics may be an effective therapy. This study examines the efficacy of the nonsystemic …

Background: Recent studies indicate that persistent intestinal inflammation in patients with
Crohn's disease (CD) might be caused by abnormal intestinal microbiota. This hypothesis …

Objective: This open-label study was conducted as a preliminary assessment of rifaximin
(200 mg TID for 16 weeks) for the treatment of active Crohn's disease in patients (n= 29) with …

Background Clinicians often employ antibiotics in Crohn's disease. Rifaximin is active
against bacteria frequently found in the intestinal mucosa of Crohn's disease patients. Aim …

The gut microbiota plays a role in promoting and maintaining inflammation in inflammatory
bowel diseases (IBD), hence the rationale for the use of antibiotics in the treatment of those …

Objectives Rifaximin, a rifamycin derivative, has been reported to induce clinical remission
of active Crohn's disease (CD), a chronic inflammatory bowel disorder. In order to …

Background Gut microbiota dysbiosis contributes to the pathogenesis of inflammatory bowel
diseases (IBD). Although the microbiota's role in IBD pathogenesis, specifically Crohn's …

Recent evidence suggests a role for gut bacteria and antibiotics in the pathophysiology and
treatment of irritable bowel syndrome (IBS), respectively. While the benefits of the antibiotic …

OBJECTIVE: The aim of this randomized controlled study was to investigate the efficacy of
ciprofloxacin compared with mesalazine in treating active Crohn's disease. METHODS …